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PURPOSE. We determined whether there is relative sparing of pupil function in glaucoma
patients with normal pressures compared to those with high pressures.
METHODS. A cross-sectional study was done of 68 patients with primary open angle glaucoma
(POAG): 38 had normal IOPs on all-day phasing before treatment (never >21 mm Hg), with
confirmed progression of glaucomatous optic neuropathy (NTG) and 30 had glaucomatous
optic neuropathy associated with elevated intraocular pressures (>25 mm Hg; HP-POAG).
The relative afferent pupillary defect (RAPD) was quantified with the RAPDx device, and
mean deviation of visual field loss was obtained from reliable Humphrey visual fields.
Outcomes measures evaluated were difference in slope between NTG and HP-POAG when
plotting: (1) RAPD score against difference in mean deviation (MD) between eyes, and (2)
RAPD score against difference in RNFL thickness between eyes.
RESULTS. The slopes for magnitude of RAPD versus difference in MD were 0.06 (95%
confidence interval [CI], 0.076, 0.044) for patients with NTG and 0.08 (95% CI, 0.109,
0.067) for those with HP-POAG. Fitting the interaction term showed a statistically significant
difference between the slopes (0.023; 95% CI [0.0017, 0.0541]; P value ¼ 0.037; HP-POAG
reference group). Thus, for difference in MD, the slope for patients with NTG was flatter than
the slope for those with HP-POAG.
CONCLUSIONS. Glaucoma patients with NTG have a lesser RAPD for a given level of intereye
difference of HVF MD, compared to patients with high IOPs. This suggests that damage to
intrinsically photosensitive retinal ganglion cells (ipRGCs) differs between the normal and
high-pressure forms of open-angle glaucoma (OAG), and supports the theory that
mitochondrial optic neuropathies may have a role in the group of diagnoses currently
termed normal tension glaucoma.
Keywords: low-tension glaucoma, mitochondria, pupils
The collaborative normal tension glaucoma (NTG) studydemonstrated that IOP reduction reduces progression in
NTG.1 However, speculation remains that factors other than
pressure have a role in NTG pathogenesis. Evidence for this
includes the relatively large prevalence difference of NTG
among different genetic populations,2 and a possible associa-
tion between NTG and migraine,3 Raynaud’s phenomenon,4
and sleep apnea.5 It has been suggested that NTG is at least
partly a mitochondrial optic neuropathy.6–8
Recent work has identified melanopsin containing intrinsi-
cally photosensitive retinal ganglion cells (ipRGCs) as part of
the input into the afferent arm of the pupillary light reflex.9
While ipRGCs are intrinsically photosensitive, they also are
activated by stimulation of retinal rods and cones.
A number of studies have found relative preservation of
ipRGCs compared to other RGCs in a range of mitochondrial
optic neuropathies.10,11 A mouse model of OPA1 found
complete preservation of ipRGCs.12 A histologic study of two
human patients with Leber’s hereditary optic neuropathy
(LHON) and one with dominant optic atrophy found that the
melanopsin-containing RGCs were relatively spared compared
to pronounced loss of total RGCs.10 Two studies have
confirmed preservation of ipRGCs in LHON with pupillome-
try.13,14 While these observations strongly suggest that ipRGCs
resist neurodegeneration caused by mitochondrial dysfunction,
the mechanism of this protection is not known.
This finding provides an explanation for the clinical
observation that patients with LHON had relative preservation
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of their pupil function for a given level of visual loss.15
Similarly, if NTG were a mitochondrial optic neuropathy, the
pupil response in NTG compared to high pressure primary
open angle glaucoma (HP-POAG) should be relatively spared
due to survival of ipRGCs in mitochondrial optic neuropa-
thies.10 ipRGCs have been shown to be damaged in HP-
POAG.16 Therefore, if the pathogenesis of NTG relates more
strongly to mitochondrial dysfunction than in HP-POAG,
patients with NTG should have relative sparing of their pupil
function.
One method of assessing pupil function is to compare the
pupil response between the patient’s two eyes. Asymmetrical
disease is reflected in asymmetrical pupil responses in the form
of a relative afferent pupil defect (RAPD). The difference
between eyes in white-on-white standard automated perimetry
Humphrey Visual Field (HVF) mean deviation (MD) is a
measure of intereye asymmetry of glaucoma damage. When
the magnitude of the RAPD is plotted against intereye
difference in MD, then the magnitude of the pupil defect
correlates with the difference in glaucomatous visual field (VF)
loss between the two eyes.17 We investigated whether there
was a significant difference in slope in patients with NTG
versus those with HP-POAG for: (1) RAPD versus difference in
MD between eyes and (2) RAPD versus difference in RNFL
between eyes.
METHOD
Subjects
Two subgroups of patients were recruited: patients with NTG
and those with HP-POAG. The NTG group underwent all day
phasing before commencing any glaucoma treatment, and
never had any IOP reading above 21 mm Hg. They also had
evidence of glaucomatous VF progression as determined by
Progressor software (Medisoft, Leeds, United Kingdom).
The HP-POAG group included patients with a measured IOP
of at least 25 mm Hg in the eye with the worse VF defect, but
no IOP reading above 40 mm Hg. They required the same disc
and VF parameters as the NTG group, but without the
requirement for VF progression. A pressure of at least 25 mm
Hg was selected to have a clear distinction concerning IOP
between the two study groups.
Patients were included only if they had a reliable HVF (false-
positive [FP] <15%, false-negative [FN] <33%, fixation loss [FL]
<20%), had completed at minimum of two HVFs before the
field used for the study, and had a glaucomatous field defect in
at least one eye that matched the site of optic disc cupping. All
patients had the same lens status in each eye (either bilaterally
phakic or bilaterally pseudophakic); the pupil assessment
compared the left and right pupils and, therefore, having no
potential confounder between the two eyes was considered
important.
Exclusion criteria for both groups were any retinal or optic
nerve disease other than glaucoma, or any other ocular disease
likely to alter VF or pupil assessment. Individuals were
excluded if they were using a topical a2 agonist or pilocarpine,
both of which are known to affect pupil size. Similarly, patients
using systemic medications known to alter pupil size, such as
opiates, also were excluded.
For each patient, RAPD magnitude was quantified by the
Konan RAPDx system (Konan Medical USA, Irvina, CA, USA).
For each eye of each patient, MD was determined using a 24-2
HVF with the SITA-standard strategy. Retinal nerve fiber layer
(RNFL) thickness was measured using the Spectralis OCT
(Heidelberg Engineering, Heidelberg, Germany), with the
global RNFL thickness parameter used. Informed consent was
obtained from all participants and the research adhered to the
tenets of the Declaration of Helsinki. Ethical review and
approval was obtained through the United Kingdom NHS
national research ethics committee (approval number 14/EM/
1011).
RAPDx Pupillometry
The commercially available RAPDx device provides automated
pupillometry with output of an ‘‘RAPD score.’’ The RAPD
score has been shown to have a strong correlation with the
difference in MD between each eye of glaucoma patients.17,18
The instrument is Food and Drug Administration (FDA;
Washington, DC, USA) approved.
Each subject was dark-adapted for at least 1 minute before
undergoing pupillometry. The RAPDx presents visual stimuli
monocularly, alternately to each eye, with the fellow eye
continuing to view a nominal background and fixation target as
a cyclopean scene.17 Bright full-field white stimuli were
presented for durations of 0.2 seconds alternating with 1.9
seconds of nominal background illuminance. The amplitude of
change in dimensions of each pupil is calculated from baseline
under nominal illumination. After one practice stimulus pair,
pupil responses elicited by a series of stimulus pairs are
averaged to assess the relative afferent pupillary defect value. A
log magnitude comparing the difference of pupil constriction
amplitudes between the two eyes was calculated automatically.
This was defined as the RAPD score in this study.
There are two methods by which the ipRGCs may be
stimulated by the RAPDx. The first is directly; that is, the
threshold retinal irradiance for ipRGC activation has been
determined as approximately 5 3 1011 photon/cm2/s at 500
nm,19 which is at the threshold of the luminance provided by
the RAPDx. Second, ipRGCs also are stimulated by retinal rods
and cones20,21 and, therefore, loss of ipRGCs is likely to
diminish the pupil response at a range of luminance levels.
Data Analysis and Statistics
Summary statistics for the outcome measures are presented as
mean and standard deviation (SD) for right/left eyes separately.
Differences were computed as left eye minus right eye values,
as the RAPD score is positive when the right eye is worse than
the left and vice versa. Plots of RAPD magnitude against
difference in HVF MD between eyes and of RAPD magnitude
against difference in RNFL between eyes are presented with
separate fitted regression lines for the NTG and HP-POAG
groups separately—R2 values from univariable linear regres-
sion are provided as a measure of fit. Significance level was set
at 5%.
To compare the slopes of RAPD magnitude between NTG
and HP-POAG, two separate linear regression models, one with
an interaction term between group and difference in HVF MD
between eyes and other with an interaction term between
group and difference in RNFL thickness between eyes, were
fitted. Coefficients are presented with respective 95% confi-
dence intervals (CIs). Sensitivity analysis, excluding observa-
tions below1.5 and above 1.5 RAPD units, was conducted to
investigate the impact of outliers on the main findings. The
criteria for defining outliers was guided by Chang et al.18
(beyond 1.5 log units RAPD, in either direction, data points
diverge from the line of best fit and correlation is less tight).
RESULTS
We recruited 68 patients with open angle glaucoma (OAG): 38
with progressive NTG and 30 with glaucomatous optic
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neuropathy associated with elevated IOPs. The mean age (SD)
of participants was 66 (11) and 65 (14) years in the NTG and
HP-POAG groups, respectively. Summary statistics for the
outcome measures are presented in Table 1 by patient group.
In Figures 1 and 2, the individual univariable regression
lines cross, suggesting that there might be a difference in the
slopes between the two groups. The R2 values indicate good
fit; that is, 61% of the variation in the magnitude of RAPD can
be explained by the difference in MD for the NTG group and,
74% of the variation in the magnitude of RAPD can be
explained by the difference in MD for the HP-POAG group.
The slopes for magnitude of RAPD versus difference in MD
were0.06 (95% CI [ 0.076, 0.044]) for patients with NTG
and0.08 (95% CI [0.109,0.067]) for those with HP-POAG.
Fitting the interaction term showed a statistically significant
difference between the slopes (0.023; 95% CI [0.0017, 0.0541];
P value ¼ 0.037; HP-POAG reference group). Thus, for
difference in MD, the slope for patients with NTG is flatter
than the slope for patients with HP-POAG. When removing
outliers (i.e., observations with RAPD below 1.5 and above
1.5 log units), this result remained significant.
The slopes for magnitude of RAPD versus difference in
RNFL thickness were 0.03 (95% CI [0.039, 0.025]) for
patients with NTG and 0.02 (95% CI [0.028, 0.019]) for
patients with HP-POAG. Fitting the interaction term showed a
statistically significant difference between the slopes (0.009;
95% CI [0.0167, 0.0006]; P value ¼ 0.036; HP-POAG
reference group). Thus, for difference in RNFL, the slope for
patients with HP-POAG is flatter than the slope for patients
with NTG. However, when removing outliers (i.e., observa-
tions with RAPD below1.5 and above 1.5 log units) as shown
in Figure 3, there was no longer evidence of a difference in
slopes between NTG and RAPD (interaction term coefficient
0.001; 95% CI [0.006, 0.009]; P value 0.73) suggesting that
the detected difference might be driven by outliers.
DISCUSSION
Our results suggested that for a given level of VF asymmetry,
patients with NTG have a lesser magnitude RAPD compared to
those with HP-POAG. This suggested relative sparing of pupil
TABLE 1. Summary Statistics for Outcome Measures by Patient Group
NTG Group,
N ¼ 38
HP-POAG Group,
N ¼ 30
Mean SD Mean SD
RAPD* 0.06 0.7 0.09 0.7
MD – Left Eye 8 5.5 4.7 4.1
MD – Right Eye 7.5 7.1 5.6 5.2
MD Difference 0.5 8.6 0.9 6.9
RNFL – Left Eye 67.2† 15† 73.7‡ 15.1‡
RNFL – Right Eye 67.2‡ 16.8‡ 70‡ 19.6‡
RNFL Difference 0.6† 18.5† 3.8‡ 26.9‡
CCT – Left Eye 539 33 544 36
CCT – Right Eye 536 30 541 34
Max IOP before
treatment
– Left Eye
18 2 29 5
Max IOP before
treatment
– Right Eye
18 2 28 5
* One patient with NTG had RAPD values above 1.5 log units and
two with NTG had RAPD values below1.5 log units.
† Missing for five patients.
‡ Missing for four patients.
FIGURE 1. Univariable regression lines. Plot of RAPD magnitude
against difference in HVF MD between eyes in respective individual
patient groups.
FIGURE 2. Univariable regression lines. Plot of RAPD magnitude
against difference in RNFL thickness between eyes in respective
individual patient groups.
FIGURE 3. Plot of RAPD magnitude against difference in RNFL
thickness between eyes in respective individual patient groups.
Univariable regression lines removing outliers (i.e., observations with
RAPD below1.5 and above 1.5 log units).
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function for a given level of field defect in patients with NTG
that most likely represents relative sparing of ipRGCs in NTG.
Several investigators have demonstrated that ipRGCs are
damaged in patients with POAG and elevated IOPs.16,22,23 Our
study suggested that NTG behaves differently and that damage
to ipRGCs may be less for patients with NTG compared to
those with elevated pressures. There is evidence that ipRGCs
are spared preferentially in mitochondrial optic neuropathies.
The term ‘‘NTG’’ may include individuals with varying
susceptibility to different optic nerve stressors, and this study
supports the idea that mitochondrial disorders may have a role
in at least a subset of these patients.
There also is evidence that damage to ipRGCs has broader
relevance to patient outcomes.24 Glaucoma is associated with
alterations of the circadian system with associated sleep
disorders.24 Light has an important role in synchronizing the
circadian system, and therefore, loss of ipRGCs compromises
the circadian rhythm.24 This is the postulated mechanism of
the finding of sleep disturbance in glaucoma patients. Although
the findings from this study may suggest that relative sparing of
ipRGCs in NTG may lead to less sleep disturbance, there also is
evidence that sleep pathology may be an underreported
complication of primary mitochondrial disease.25 A number
of groups are investigating sleep disturbance in glaucoma, but
these results suggest that attention should be given to NTG
subgroups within these studies. These findings raise the
possibility that a noninvasive technique may be able to identify
patients in whom mitochondrial dysfunction had a significant
role. However, this clearly would need extensive further work.
At present IOP-lowering is the only proven intervention for
any glaucoma, yet many patients continue to deteriorate
despite medical IOP-lowering, and go on to have surgical
lowering of IOP with all its attendant risks.26 This applies
equally to patients with NTG, but the lower pretreatment IOP
leads to a higher risk of harm from hypotony.27 The ability to
identify patients with mitochondrial dysfunction may influence
surgical decisions by reassessing whether there is a different
risk–benefit profile of IOP lowering surgery in this subgroup.
Further, it may be that patients with a greater influence of
mitochondrial dysfunction could be targeted to better identify
the most appropriate patients in whom to assess neuroprotec-
tive therapies.
Finally, this study also confirms previous findings of a tight
correlation between RAPD magnitude and visual function
measured with automated perimetry. Any apparent uncoupling
of this tight correlation has implications for clinical practice: a
disproportionately large RAPD in symmetrical glaucoma, or no
RAPD in apparently asymmetrical glaucoma should prompt
consideration of an alternative (or additional) diagnosis to
glaucoma.
There are limitations to our study. Although our finding was
positive for HVF MD versus RAPD, it was unexpected to find
that there also was a significant difference in slope between
groups on the structure outcome. To maximize recruitment, we
included all patients irrespective of the magnitude of the RAPD.
However, results of other investigators have suggested an
uncoupling of the linear relationship between RAPD and
intereye MD difference once the RAPD magnitude is >1.5 log
units,18 a finding in keeping with our results. This may be
because of the RNFL thickness ‘‘floor.’’ It does not fall below 30
lm even in eyes with end-stage optic neuropathies with no light
perception.28 Data points with a large difference in RNFL
thickness between eyes are most likely to be affected by this
floor effect: if there was no floor effect we would expect a larger
RNFL difference. Once we limited the analysis to patients with
RAPD magnitude <1.5 log units, the difference between the
slopes for HVF versus RAPD remained significant, while for
RNFL versus RAPD there was no longer evidence of a difference
in slopes between groups. Finally, we required evidence of
progression for patients with NTG, but not for those with high
pressures. Patients with NTG likely have a higher probability of
harboring an alternative or additional diagnosis to glaucoma, and
we wanted to be confident of the NTG phenotyping. Although
this was a difference between the groups, we believe it unlikely
to have led to any significant bias.
A possible alternative hypothesis to explain our results
relates to the suggestion that NTG affects the central VF more
commonly than HP-POAG,29 and that the macula appears be to
affected relatively early in the glaucomatous disease process.30
These observations raise the possibility that undetected central
field defects may lead to a greater RAPD for the same level of
measured MD, which potentially would lead to a flatter curve
when plotting RAPD against MD, which was observed in our
study. Although evidence for early macula involvement in
glaucoma is relatively strong, evidence that the central field is
affected more in NTG is conflicting.29 For central field changes
to explain our findings, they would need to be predominantly
unilateral; however, only 8 of the 38 patients with NTG had an
eye with a MD that was less than 1 dB and, therefore, most
participants had bilateral glaucoma. As the study compares
difference between eyes (rather than investigating absolute
values), it is likely that this effect would be somewhat
mitigated, should it, indeed, be present.
One strength of this study is its extremely tight phenotyping
with documented normal pressures on phasing, correlated
field loss, and disc damage, and confirmed VF progression in
the normotensive group. This minimizes the chance that we
have included subjects with nerves damaged by prior ischemic
events or compressive lesions that might masquerade as NTG.
That there is no significant difference in central corneal
thickness between groups suggests that we have captured
‘‘true’’ NTG, rather than ‘‘apparent’’ NTG due to artificially low
IOP measurements.
Different wavelengths and light intensities will lead to
different ratios of stimulation of ipRGCs and photoreceptors,31
and the relatively low luminance of the RAPDx stimulus means
that it is unlikely to have activated directly the ipRGCs through
melanopsin, but rather via activation of rods and cones.
However, the preferential preservation of the ipRGCs none-
theless would produce the same result as we present here.
In summary, patients with HP-POAG have a greater RAPD
for a given level of intereye VF asymmetry, compared to
patients with normal pressure glaucoma. One interpretation of
this result is that damage to ipRGCs differs between the normal
and high-pressure forms of OAG, which would support the
theory that mitochondrial optic neuropathies may have a role
in the group of diagnoses currently termed NTG.
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